Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.
"Are research peptides legal?" is the most common question a practice manager asks before opening an account, and the honest answer is that US law does not have a category called "research peptide" at all. This article explains how the Federal Food, Drug, and Cosmetic Act (FDCA) classifies a peptide, what a "research use only" label does and does not do, what federal enforcement looked like from 2023 through 2026, where state law comes in, and what a practice should keep on file. It is a regulatory explainer, not legal advice.
The short answer: legality turns on intended use, not on the molecule
A peptide sold, labeled and used as an in vitro research reagent is a chemical, and buying it for laboratory research is lawful. The same peptide becomes a "drug" under federal law the moment anyone in the chain of distribution intends it for use in people or animals, and because almost none of the peptides in a research catalog has an approved marketing application, it then becomes an unapproved new drug that cannot lawfully be shipped across state lines. The chemical identity never changes; the legal status follows the intent.
Two further points frame everything below. The common research peptides are not scheduled under the Controlled Substances Act, so this is a food-and-drug-law question. And the rules reach sellers and buyers differently: FDA's actions have targeted vendors whose marketing contradicts their labels, while a buying practice's exposure comes from how it stores, documents and uses what it bought. Our article on what "research use only" means covers the label itself in more depth.
How the FDCA defines a drug
Section 201(g)(1) of the FDCA, codified at 21 U.S.C. 321(g)(1), defines a drug in part as an article intended for use in the diagnosis, mitigation or prevention of disease (the statute lists several disease-related purposes), and separately as an article, other than food, intended to affect the structure or any function of the body of man or other animals. Nothing in that definition refers to chemical class or purity; a vial of lyophilized peptide is a drug if, and only if, it is intended for one of those purposes.
Section 201(p), 21 U.S.C. 321(p), then defines a "new drug" as a drug that is not generally recognized, among qualified experts, as safe and effective for the uses suggested in its labeling. Section 505(a), 21 U.S.C. 355(a), prohibits introducing a new drug into interstate commerce without an approved application, and section 301(d), 21 U.S.C. 331(d), makes doing so a prohibited act. Every FDA warning letter to a peptide vendor cites this four-step chain: intended use makes it a drug, lack of general recognition makes it a new drug, no approved application makes it unapproved, and shipping it is prohibited.
Legality is therefore assessed product by product and seller by seller. NN9535 and LY3298176, which have approved applications held by their sponsors, are still unapproved new drugs when a third party sells them under a different intended use, because approval belongs to a specific product, not to the molecule. The FDA status table lists which catalog compounds exist as approved products and under what names.
What a "research use only" label does, and what it cannot do
The phrase "research use only" has exactly one regulatory definition, and it is not about peptides. Under 21 CFR 809.10(c)(2)(i), an in vitro diagnostic product in the laboratory research phase of development must carry the statement "For Research Use Only. Not for use in diagnostic procedures." That rule governs diagnostic kits and reagents. For a peptide, "research use only" is simply a labeling statement by which the seller declares its intended use, and it carries weight only to the extent that everything else the seller says and does is consistent with it.
That consistency test is written into 21 CFR 201.128. The regulation says intended use refers to the objective intent of the people responsible for labeling, and that this intent may be shown by their expressions, by the design or composition of the article, or by the circumstances surrounding its distribution, including labeling claims, advertising matter, and oral or written statements. It adds that intended use can change downstream: a distributor or seller who intends an article for a different use than the manufacturer did is responsible for labeling it accordingly. In plain terms, a research-use label protects a vendor whose product pages discuss chemistry and documentation, and it does nothing for a vendor whose product pages, newsletters or social media describe effects in people.
The same logic reaches reagents sold alongside the peptide: 2026 warning letters cited vendors' sale of bacteriostatic water as a solvent for their peptides as further evidence of intended human use. The supply itself is lawful; the context in which it was offered was the problem.
The 2023 to 2026 enforcement landscape
Federal activity in this period ran on two parallel tracks, one about compounding pharmacies and one about research-chemical sellers, and the two are often confused. On the compounding track, in September 2023 FDA placed a group of nominated peptides, including BPC-157, AOD-9604, CJC-1295, ipamorelin, LL-37 and dihexa, into "Category 2" of its interim policy on bulk substances for section 503A compounding, meaning the agency had identified significant safety risks, chiefly immunogenicity and absent human exposure data. In April 2026 the agency revised that list and moved a dozen peptides out of Category 2, and on July 23 and 24, 2026 its Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax and Epitalon as candidates for the 503A bulks list. Trade press reported narrow advisory votes in favor of most of them; FDA's own reviewers had recommended against listing, and no final rule had been published when this article was written. Whatever the outcome, that track concerns what licensed pharmacies may compound. It does not create a research category and does not approve any compound.
On the research-seller track, FDA's Office of Unapproved Drugs and Labeling Compliance issued a series of warning letters beginning in December 2024. The letter to Summit Research Peptides (December 10, 2024) named NN9535, LY3437943, LY3298176, AM833 and mazdutide, acknowledged the "research use only" labels, and relied on product-page language and a Facebook post to conclude the products were intended as drugs for human use. Letters in 2026 followed the same template: Gram Peptides (March 31, 2026; LY3437943, LY3298176 and bacteriostatic water), Wholesale Peptide (June 17, 2026; gonadorelin and Prostamax), and a group of letters dated August 24, 2026 including Peak Performance Peptides (LY3437943, NN9535, SS-31, PT-141, TH9507 and bacteriostatic water). Each letter states that evidence from the website established intended human use despite the labels, cites sections 201(g)(1), 201(p), 505(a) and 301(d), and requests a written response within fifteen working days.
No letter we reviewed objects to the sale of a peptide as a research chemical as such; every letter objects to marketing that contradicts the research label.
Compounded peptides are a different thing from research vials
Section 503A of the FDCA allows a licensed pharmacist or physician to compound a drug for an identified individual under a valid prescription, exempt from premarket approval, from current good manufacturing practice requirements, and from the "adequate directions for use" labeling rule, provided the bulk substance meets a USP or NF monograph, is a component of an approved drug, or appears on an FDA list. Section 503B, added by the Drug Quality and Security Act of 2013, created registered outsourcing facilities that compound under CGMP, may ship without prescriptions for office stock, and must report adverse events. FDA's own summary is blunt: compounded drugs are not approved, and the agency does not verify their safety, effectiveness or quality before marketing.
A research vial fits neither section. It is not compounded for an identified person, not made by a registered outsourcing facility, and not labeled for human use at all; it is a chemical reagent with a certificate of analysis. Confusing approved drug, compounded drug and research reagent is the most common error in online discussion of peptide legality, and our article on 503A, 503B and research use only separates them line by line.
Where state law comes in
Federal law sets the floor; states regulate pharmacy practice, wholesale drug distribution and professional licensure, and most have food-and-drug statutes whose definitions of "drug" mirror the federal intended-use test. A state board can therefore reach conduct FDA has not acted on, such as a licensee keeping unapproved drugs in a clinical setting. States differ on what counts as wholesale distribution, whether research chemicals require registration, and how closely boards examine purchase records.
Because the variation is real and changes, this article does not list state-by-state rules. Ask your state board of pharmacy and your own counsel whether purchasing research reagents for a documented laboratory purpose requires any license or registration, and whether any state rule restricts where such reagents may be stored relative to clinical inventory.
What a practice or laboratory should keep on file
| Record | What it shows | Why it matters |
|---|---|---|
| Written research purpose or protocol | The laboratory question the reagent is bought for | Establishes your own intended use in your own words |
| Research-use attestation | Signed acknowledgment that material is for in vitro use only | Matches the vendor's labeling; expected by any serious supplier |
| Purchase records with lot numbers | Date, vendor, product, lot, quantity | Links each vial to its certificate and to a purpose |
| Lot-matched certificates of analysis | Identity, purity, content, endotoxin, sterility, metals | Documents what the reagent is; see how to read a COA |
| Storage log | Location, temperature, separation from clinical stock | Shows the reagent is handled as a reagent |
| Disposal records | Date and method for expired or spent material | Closes the chain of custody |
This is the same documentation a well-run laboratory keeps for any reagent. Its value is that the practice can show its intended use was research from the day of purchase, which is the only question federal law actually poses.
Frequently Asked Questions
Are research peptides legal to buy in the United States?
Buying a peptide labeled and documented as an in vitro research reagent, for a laboratory purpose, is lawful under federal law. The same peptide becomes an unapproved new drug if it is intended for use in people or animals, and most research peptides have no approved application. State licensing rules can add requirements, so a practice should confirm with its state board.
Does a "research use only" label make a peptide legal to sell?
Only if the seller's whole sales context agrees with it. Under 21 CFR 201.128, intended use is shown by labeling, advertising, statements and the circumstances of distribution, and FDA warning letters from 2024 through 2026 state that a research-use label does not control when a vendor's website describes the products as drugs for human use.
Is BPC-157 legal in the US?
BPC-157 is not an approved drug and is not a controlled substance. It may be sold and bought as a research chemical for laboratory use. FDA placed it in Category 2 of its 503A compounding list in 2023, removed it in April 2026, and took it to an advisory committee in July 2026; those steps concern pharmacy compounding and had produced no final listing when this article was written.
What is the difference between a compounded peptide and a research peptide?
A compounded peptide is made by a licensed pharmacy or outsourcing facility under section 503A or 503B of the FDCA for use in people, and FDA states that compounded drugs are not approved. A research peptide is a chemical reagent supplied for in vitro laboratory work with a certificate of analysis; it is neither compounded nor approved and is not labeled for human use.
Citations
- 21 U.S.C. 321, Definitions; generally (FD&C Act section 201, including 201(g)(1) "drug" and 201(p) "new drug"). Legal Information Institute, Cornell Law School. law.cornell.edu
- 21 U.S.C. 355, New drugs (FD&C Act section 505). Legal Information Institute. law.cornell.edu
- 21 U.S.C. 331, Prohibited acts (FD&C Act section 301). Legal Information Institute. law.cornell.edu
- 21 CFR 201.128, Meaning of "intended uses". Electronic Code of Federal Regulations. ecfr.gov
- 21 CFR 809.10, Labeling for in vitro diagnostic products, paragraph (c)(2)(i). Electronic Code of Federal Regulations. ecfr.gov
- US FDA. Warning Letter to Summit Research Peptides, December 10, 2024. fda.gov
- US FDA. Warning Letter to Gram Peptides, March 31, 2026. fda.gov
- US FDA. Warning Letter to Wholesale Peptide, June 17, 2026. fda.gov
- US FDA. Warning Letter to Peak Performance Peptides, August 24, 2026. fda.gov
- US FDA. Human Drug Compounding Laws (sections 503A and 503B; Drug Quality and Security Act of 2013). fda.gov
- US FDA. Compounding and the FDA: Questions and Answers. fda.gov
- US FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (interim policy categories; content current as of May 14, 2026). fda.gov
- US FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026). fda.gov
- US FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.
Related research
- What 'Research Use Only' Actually Means on a Peptide Label
- How to Vet a Research Peptide Vendor: A 12-Point Checklist
- FDA Status of Common Research Peptides: A Reference Table
- What Are Research Peptides? Grades, Formats, and How Labs Use Them
- What a Lot Number Is For, and How to Match a Vial to Its Certificate
Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.
